Aisling Capital’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-210,000
| Closed | -$88K | – | 8 |
|
|
2018
Q4 | $88K | Hold |
210,000
| – | – | 0.02% | 8 |
|
|
2018
Q3 | $202K | Hold |
210,000
| – | – | 0.04% | 9 |
|
|
2018
Q2 | $510K | Hold |
210,000
| – | – | 0.07% | 9 |
|
|
2018
Q1 | $502K | Hold |
210,000
| – | – | 0.09% | 10 |
|
|
2017
Q4 | $504K | Hold |
210,000
| – | – | 0.1% | 12 |
|
|
2017
Q3 | $662K | Hold |
210,000
| – | – | 0.11% | 13 |
|
|
2017
Q2 | $844K | Hold |
210,000
| – | – | 0.14% | 14 |
|
|
2017
Q1 | $777K | Hold |
210,000
| – | – | 0.14% | 16 |
|
|
2016
Q4 | $407K | Buy |
210,000
+9,000
| +4% | +$32.6K | 0.09% | 18 |
|
|
2016
Q3 | $1.25M | Hold |
201,000
| – | – | 0.26% | 18 |
|
|
2016
Q2 | $905K | Hold |
201,000
| – | – | 0.21% | 21 |
|
|
2016
Q1 | $2.11M | Hold |
201,000
| – | – | 0.42% | 19 |
|
|
2015
Q4 | $5.93M | Hold |
201,000
| – | – | 1.02% | 17 |
|
|
2015
Q3 | $6.35M | Hold |
201,000
| – | – | 1.12% | 18 |
|
|
2015
Q2 | $11.9M | Hold |
201,000
| – | – | 1.77% | 15 |
|
|
2015
Q1 | $21.5M | Hold |
201,000
| – | – | 2.81% | 12 |
|
|
2014
Q4 | $18.9M | Hold |
201,000
| – | – | 2.86% | 13 |
|
|
2014
Q3 | $15.4M | Hold |
201,000
| – | – | 2.99% | 13 |
|
|
2014
Q2 | $18.1M | Buy |
+201,000
| New | +$12.3M | 5.22% | 9 |
|
Aisling Capital's PTX Position: Q1 2019 in Review
Aisling Capital sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q1 2019, closing a stake of 210,000 shares — an estimated $88K sold.
Aisling Capital first reported a position in PTX in Q2 2014 and held it in 19 quarters. The position peaked at $21.5M in Q1 2015. 1 fund tracked by Wall St. Rank holds PTX as of Q1 2019.
- Aisling Capital reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q1 2019 after selling out during the quarter.
- Aisling Capital sold 210,000 Pernix Therapeutics Holdings, Inc. shares in Q1 2019, an estimated $88K.
- Aisling Capital first reported a position in Pernix Therapeutics Holdings, Inc. in Q2 2014 and held it in 19 quarters.
- Aisling Capital's Pernix Therapeutics Holdings, Inc. position peaked at $21.5M in Q1 2015.
- 1 fund tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q1 2019.
Based on Aisling Capital's 13F filing for Q1 2019, filed 7 May 2019.